Epiphany Biosciences Reports Initiation Of Phase 2 Study Of Valomaciclovir For The Treatment Of Acute Infectious Mononucleosis
Epiphany Biosciences announced, the initiation of a Phase 2 clinical trial with valomaciclovir (EPB-348) for the treatment and management of acute infectious mononucleosis. [click link for full article]
More: continued here
Filed under: Clinical Trials on December 9th, 2007